{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:56:33Z","timestamp":1793141793370,"version":"4.5.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011789","name":"Department of Science and Technology of Jilin Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011789","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The coexistence of hepatic fibrosis (HF) and inflammatory bowel disease (IBD) represents a significant clinical concern due to their poorly characterized shared pathogenic mechanisms. Current limitations in identifying common biomarkers for comorbid cases impede early dual diagnosis and therapeutic interventions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Differentially expressed genes (DEGs) were screened, followed by Weighted Gene Co-expression Network Analysis (WGCNA) to identify disease-associated modules. The key diagnostic biomarkers were determined via a protein-protein interaction (PPI) network combined with two machine learning algorithms. The logistic regression model was subsequently developed based on these key genes. Immune cell infiltration profiling of both diseases was assessed via the CIBERSORT algorithm. The construction of genes-miRNAs and genes-TFs (Transcription Factors) regulatory networks were based on the NetworkAnalyst website. Potential drug-gene interactions were predicted utilizing the DSigDB database. The expression and distribution of these genes were validated through single-cell sequencing analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A sum of 119 up-regulated genes and 17 down-regulated genes were screened, which were enriched in categories associated with immune cell infiltration and chemotaxis, cytokine regulation, metabolic processes, enzymatic activity, and extracellular matrix deposition, based on enrichment analysis. WGCNA revealed four disease-associated gene modules. Four shared diagnostic genes for both diseases were screened, including MMP2, COL1A2, STAT1, and CXCL1. ROC curve analysis confirmed robust diagnostic performance as AUC &amp;gt; 0.7 for individual genes and AUC &amp;gt; 0.85 for combined model. M1 macrophages were significantly increased in both pathologies of diseases. A total of 462 drugs were predicted targeting these biomarkers in the DSigDB database. The four key diagnostic gene expression patterns across diverse cell subpopulations were visualized by single-cell sequencing analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>MMP2, COL1A2, CXCL1, and STAT1 were identified as shared biomarkers for IBD and HF, providing a molecular basis for early diagnosis and precision medicine approaches. It elucidated the similarities between HF and IBD in terms of immunity, metabolism, and fibrosis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1533246","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T05:39:58Z","timestamp":1747028398000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Exploring shared pathogenic mechanisms and biomarkers in hepatic fibrosis and inflammatory bowel disease through bioinformatics and machine learning"],"prefix":"10.3389","volume":"16","author":[{"given":"Shangkun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingran","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"Kisseleva","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/med.21893","article-title":"Inflammatory bowel disease biomarkers","volume":"42","author":"Liu","year":"2022","journal-title":"Med Res Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12568","article-title":"Intestinal strictures in crohn\u2019s disease: an update from 2023","volume":"12","author":"Liu","year":"2024","journal-title":"United Eur Gastroenterol J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.cgh.2022.01.039","article-title":"Increased risk of mafld and liver fibrosis in inflammatory bowel disease independent of classic metabolic risk factors","volume":"21","author":"Rodriguez-Duque","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41572-025-00600-x","article-title":"Primary sclerosing cholangitis","volume":"11","author":"Manns","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i25.3762","article-title":"Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment","volume":"27","author":"Axiaris","year":"2021","journal-title":"World J Gastroenterol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"396","DOI":"10.5009\/gnl210081","article-title":"Clinical course of hepatitis B viral infection in patients undergoing anti-tumor necrosis factor \u0391 Therapy for inflammatory bowel disease","volume":"16","author":"Lee","year":"2022","journal-title":"Gut Liver"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/mcg.0000000000001640","article-title":"Impact of cirrhosis on outcomes in inflammatory bowel disease hospitalizations","volume":"56","author":"Taneja","year":"2022","journal-title":"J Clin Gastroenterol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(24)00437-0","article-title":"Staging liver fibrosis and cirrhosis using non-invasive tests in people with chronic hepatitis B to inform who 2024 guidelines: A systematic review and meta-analysis","volume":"10","author":"Liguori","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v17.i2.100033","article-title":"Modern ultrasound techniques for diagnosing liver steatosis and fibrosis: A systematic review with a focus on biopsy comparison","volume":"17","author":"Pozowski","year":"2025","journal-title":"World J Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(24)00265-6","article-title":"International expert guidance for defining and monitoring small bowel strictures in crohn\u2019s disease on intestinal ultrasound: A consensus statement","volume":"9","author":"Lu","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)02586-2","article-title":"Crohn\u2019s disease","volume":"403","author":"Dolinger","year":"2024","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Le Berre","year":"2023","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50116","article-title":"Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats","volume":"37","author":"Lorenzo-Z\u00fa\u00f1iga","year":"2003","journal-title":"Hepatology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.12.019","article-title":"Altered profile of human gut microbiome is associated with cirrhosis and its complications","volume":"60","author":"Bajaj","year":"2014","journal-title":"J Hepatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae096","article-title":"Inflammatory bowel disease associated with primary sclerosing cholangitis is associated with an altered gut microbiome and bile acid profile","volume":"18","author":"Leibovitzh","year":"2024","journal-title":"J Crohns Colitis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.725390","article-title":"Molecular and cellular mediators of the gut-liver axis in the progression of liver diseases","volume":"8","author":"Bruneau","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1053\/j.gastro.2024.06.032","article-title":"Gut pathobiont-derived outer membrane vesicles drive liver inflammation and fibrosis in primary sclerosing cholangitis-associated inflammatory bowel disease","volume":"167","author":"Dorner","year":"2024","journal-title":"Gastroenterology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-023-00807-x","article-title":"Hepatic inflammatory responses in liver fibrosis","volume":"20","author":"Hammerich","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00543-0","article-title":"Revisiting fibrosis in inflammatory bowel disease: the gut thickens","volume":"19","author":"D\u2019Alessio","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.immuni.2019.03.017","article-title":"Cytokine networks in the pathophysiology of inflammatory bowel disease","volume":"50","author":"Friedrich","year":"2019","journal-title":"Immunity"},{"key":"B22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00011-025-02017-4","article-title":"Interlukin-23 inhibitors as an induction and maintenance therapy for moderate to severe ulcerative colitis: A systematic review and meta\u2212Analysis of randomized controlled trials","volume":"74","author":"Saab","year":"2025","journal-title":"Inflammation Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.100572","article-title":"The vivid-1 study: A novel methodological approach provides further evidence of efficacy of selective il-23 inhibition in crohn\u2019s disease","volume":"6","author":"Cappello","year":"2025","journal-title":"Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2024.05.003","article-title":"Metabolic reprogramming in liver fibrosis","volume":"36","author":"Horn","year":"2024","journal-title":"Cell Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29544","article-title":"Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis","volume":"67","author":"Krenkel","year":"2018","journal-title":"Hepatology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"8568","DOI":"10.1038\/s41598-019-45012-6","article-title":"Infiltrating ccr2(+) monocytes and their progenies, fibrocytes, contribute to colon fibrosis by inhibiting collagen degradation through the production of timp-1","volume":"9","author":"Kuroda","year":"2019","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/003655201750313397","article-title":"Coordinate upregulation of interleukin-8 and growth-related gene product-alpha is present in the colonic mucosa of inflammatory bowel","volume":"36","author":"Imada","year":"2001","journal-title":"Scand J Gastroenterol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.immuni.2018.09.018","article-title":"Distinct compartmentalization of the chemokines cxcl1 and cxcl2 and the atypical receptor ackr1 determine discrete stages of neutrophil diapedesis","volume":"49","author":"Girbl","year":"2018","journal-title":"Immunity"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aar7754","article-title":"Type 3 cytokines il-17a and il-22 drive tgf-\u0392-dependent liver fibrosis","volume":"3","author":"Fabre","year":"2018","journal-title":"Sci Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1497095","article-title":"The role of the interleukin family in liver fibrosis","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-329963","article-title":"Fibrosis in ibd: from pathogenesis to therapeutic targets","volume":"73","author":"Rieder","year":"2024","journal-title":"Gut"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000001302","article-title":"Pre-B-cell leukemia transcription factor 1 contributes to liver fibrosis by enabling il-7 signaling in hepatic stellate cells","author":"Zhao","year":"2025","journal-title":"Hepatology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/jimmun\/vkaf014","article-title":"Novel ror\u03b3t inverse agonists limit il-17-mediated liver inflammation and fibrosis","author":"Dabbaghizadeh","year":"2025","journal-title":"J Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114300","article-title":"Triptolide combined with salvianolic acid B alleviates ccl(4)-induced liver fibrosis by suppressing the th17\/il-17a axis","volume":"150","author":"Jiang","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.5966\/sctm.2014-0199","article-title":"Long-term results of adipose-derived stem cell therapy for the treatment of crohn\u2019s fistula","volume":"4","author":"Cho","year":"2015","journal-title":"Stem Cells Transl Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1053\/j.gastro.2017.12.020","article-title":"Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with crohn\u2019s disease","volume":"154","author":"Pan\u00e9s","year":"2018","journal-title":"Gastroenterology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1093990","article-title":"The immunomodulatory role of matrix metalloproteinases in colitis-associated cancer","volume":"13","author":"He","year":"2023","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20123077","article-title":"Post-translational modification-dependent activity of matrix metalloproteinases","volume":"20","author":"Madzharova","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2003.08.002","article-title":"Collagens\u2014Structure, function, and biosynthesis","volume":"55","author":"Gelse","year":"2003","journal-title":"Advanced Drug Delivery Rev"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-020-0497-0","article-title":"Betulinic acid hydroxamate prevents colonic inflammation and fibrosis in murine models of inflammatory bowel disease","volume":"42","author":"Prados","year":"2020","journal-title":"Acta Pharmacologica Sin"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2019.12.183","article-title":"Hepatoprotective effect of a fucoidan extract from sargassum fluitans borgesen against ccl(4)-induced toxicity in rats","volume":"145","author":"Chale-Dzul","year":"2020","journal-title":"Int J Biol Macromol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197034","article-title":"Redox regulation of stat1 and stat3 signaling","volume":"21","author":"Butturini","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1054472","article-title":"Transcriptional inhibition of stat1 functions in the nucleus alleviates th1 and th17 cell-mediated inflammatory diseases","volume":"13","author":"Park","year":"2022","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s42003-025-07843-0","article-title":"Stat1 mediates the pro-inflammatory role of gbp5 in colitis","volume":"8","author":"Li","year":"2025","journal-title":"Commun Biol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae031","article-title":"Histological outcomes and jak-stat signalling in ulcerative colitis patients treated with tofacitinib","volume":"18","author":"van Gennep","year":"2024","journal-title":"J Crohns Colitis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12967-025-06155-5","article-title":"Ifn-\u0393-mediated inhibition of jak\/stat signaling via nano-scutellarin treatment is an efficient strategy for ameliorating liver fibrosis","volume":"23","author":"Wang","year":"2025","journal-title":"J Transl Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.8106","article-title":"Ginkgetin exhibits antifibrotic effects by inducing hepatic stellate cell apoptosis via stat1 activation","volume":"38","author":"Wang","year":"2024","journal-title":"Phytother Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020792","article-title":"Cxcl1: gene, promoter, regulation of expression, mrna stability, regulation of activity in the intercellular space","volume":"23","author":"Korbecki","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27921","article-title":"Short- or long-term high-fat diet feeding plus acute ethanol binge synergistically induce acute liver injury in mice: an important role for cxcl1","volume":"62","author":"Chang","year":"2015","journal-title":"Hepatology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19041145","article-title":"Cd147 promotes cxcl1 expression and modulates liver fibrogenesis","volume":"19","author":"Shi","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2023.167013","article-title":"Transcriptome analysis identifies genetic risk markers and explores the pathogenesis for inflammatory bowel disease","volume":"1870","author":"Wang","year":"2024","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae292","article-title":"New insights into the pathogenesis of intestinal fibrosis in inflammatory bowel diseases: focusing on intestinal smooth muscle cells","volume":"31","author":"Kalafateli","year":"2025","journal-title":"Inflammation Bowel Dis"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16131","article-title":"Osteopontin promotes cholangiocyte secretion of chemokines to support macrophage recruitment and fibrosis in mash","volume":"45","author":"Coombes","year":"2025","journal-title":"Liver Int"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.803037","article-title":"Macrophage polarization and its role in liver disease","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2019.4395","article-title":"Margatoxin mitigates ccl4\u2212Induced hepatic fibrosis in mice via macrophage polarization, cytokine secretion and stat signaling","volume":"45","author":"Wu","year":"2020","journal-title":"Int J Mol Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1545468","article-title":"Artesunate alleviated murine ulcerative colitis by regulating immune response through inhibiting endoplasmic reticulum stress","volume":"16","author":"Yin","year":"2025","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.05.022","article-title":"Cytotherapy with M1-polarized macrophages ameliorates liver fibrosis by modulating immune microenvironment in mice","volume":"67","author":"Ma","year":"2017","journal-title":"J Hepatol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-023-02359-8","article-title":"Role of the pioneer transcription factor gata2 in health and disease","volume":"101","author":"Aktar","year":"2023","journal-title":"J Mol Med (Berl)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2017.48","article-title":"Foxc1: an emerging marker and therapeutic target for cancer","volume":"36","author":"Han","year":"2017","journal-title":"Oncogene"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1533246\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T05:40:01Z","timestamp":1747028401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1533246\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":59,"alternative-id":["10.3389\/fimmu.2025.1533246"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1533246","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"article-number":"1533246"}}